ALX Oncology Holdings Statistics
Want to see ALXO full AI Analyst Report?
ALX Oncology Holdings (ALXO) Stock Statistics & Valuation Metrics
Total Valuation
ALX Oncology Holdings has a market cap or net worth of $153.49M. The enterprise value is $153.58M.
- Market Cap
- $153.49M
- Enterprise Value
- $153.58M
Share Statistics
ALX Oncology Holdings has 138,277,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 138,277,000
- Owned by Insiders
- 9.79%
- Owned by Institutions
- 14.22%
Financial Efficiency
ALX Oncology Holdings’s return on equity (ROE) is -3.91 and return on invested capital (ROIC) is -261.95%.
- Return on Equity (ROE)
- -3.91
- Return on Assets (ROA)
- -1.72
- Return on Invested Capital (ROIC)
- -261.95%
- Return on Capital Employed (ROCE)
- -3.02
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.12M
- Employee Count
- 48
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of ALX Oncology Holdings is -0.99. ALX Oncology Holdings’s PEG ratio is -0.01.
- PE Ratio
- -0.99
- PS Ratio
- 0.00
- PB Ratio
- 1.12
- Price to FCF
- -2.18
- Price to Operating Cash Flow
- -2.15
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, ALX Oncology Holdings had revenue of 0 and earned -101.69M in profits. Earnings per share was -1.90.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -104.02M
- Pretax Income
- -101.69M
- Net Income
- -101.69M
- EBITDA
- -99.39M
- Earnings Per Share (EPS)
- -1.90
Cash Flow
In the last 12 months, operating cash flow was -70.78M and capital expenditures -172,000, giving a free cash flow of -70.95M billion.
- Operating Cash Flow
- -70.78M
- Free Cash Flow
- -70.95M
- Free Cash Flow per Share
- -0.52
Dividends & Yields
ALX Oncology Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -45.61%
- Earnings Yield
- -53.01%
Stock Price Statistics
- Beta
- 1.00
- 52-Week Price Change
- -14.50%
- 50-Day Moving Average
- 1.44
- 200-Day Moving Average
- 1.83
- Relative Strength Index (RSI)
- 43.53
- Average Volume (3m)
- 1.15M
Important Dates
ALX Oncology Holdings upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 11, 2027
- Ex-Dividend Date
- ―
Financial Position
ALX Oncology Holdings as a current ratio of 2.07, with Debt / Equity ratio of 20.08%
- Current Ratio
- 2.07
- Quick Ratio
- 2.07
- Debt to Market Cap
- 0.09
- Net Debt to EBITDA
- 0.11
- Interest Coverage Ratio
- -64.93
Taxes
In the past 12 months, ALX Oncology Holdings has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
ALX Oncology Holdings EV to EBITDA ratio is -1.81, with an EV/FCF ratio of -2.01.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.81
- EV to Free Cash Flow
- -2.01
- EV to Operating Cash Flow
- -2.01
Balance Sheet
ALX Oncology Holdings has $138.23M in cash and marketable securities with $9.71M in debt, giving a net cash position of $128.52M billion.
- Cash & Marketable Securities
- $138.23M
- Total Debt
- $9.71M
- Net Cash
- $128.52M
- Net Cash Per Share
- $0.93
- Tangible Book Value Per Share
- $1.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for ALX Oncology Holdings is $4.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $4.33
- Price Target Upside
- 286.90% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 48.20%
Scores
- Smart Score
- 5
- AI Score
- 43
